Angela Furlanetto
Dimock Stratton LLP, Canada
Title: Biologics & Biosimilars: The Current Litigation Landscape in Canada
Biography
Biography: Angela Furlanetto
Abstract
What’s new in Canada? New biologic approvals by Health Canada for subsequent entry biologics (SEBs) and a review of Canadian litigation involving biologics, including Canada’s first biologics decision in a patent infringement action AbbVie Corporation v. Janssen Inc., 2014 FC 55,involving the drug Stelara (ustekinumab), along with the Federal Court of Appeal decision (2014 FCA 242) to set aside the decision of the trial judge and remit the case back to the court for a new trial. The next steps and what is on the horizon for Canadian litigation.
